The above findings suggest that NGI-1 inhibits N-glycosylation of EGFR to blocks its signaling activity, thus alleviating EGFR-mediated resistance to lenvatinib in HCC cells. This evidence concerns the gene EGFR and hepatocellular carcinoma.